583 Shares in Axon Enterprise, Inc (NASDAQ:AXON) Acquired by Heartland Bank & Trust Co

Heartland Bank & Trust Co acquired a new stake in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) during the first quarter, according to its most recent filing with the SEC. The firm acquired 583 shares of the biotechnology company's stock, valued at approximately $307,000.

A number of other hedge funds have also recently bought and sold shares of AXON. Brighton Jones LLC bought a new position in Axon Enterprise in the 4th quarter valued at $480,000. Global Retirement Partners LLC boosted its position in Axon Enterprise by 23.1% in the 4th quarter. Global Retirement Partners LLC now owns 974 shares of the biotechnology company's stock valued at $579,000 after buying an additional 183 shares during the last quarter. Ieq Capital LLC boosted its position in Axon Enterprise by 10.5% in the 4th quarter. Ieq Capital LLC now owns 3,149 shares of the biotechnology company's stock valued at $1,872,000 after buying an additional 298 shares during the last quarter. Concurrent Investment Advisors LLC boosted its position in Axon Enterprise by 12.1% in the 4th quarter. Concurrent Investment Advisors LLC now owns 877 shares of the biotechnology company's stock valued at $521,000 after buying an additional 95 shares during the last quarter. Finally, Transcend Capital Advisors LLC boosted its position in Axon Enterprise by 3.6% in the 4th quarter. Transcend Capital Advisors LLC now owns 726 shares of the biotechnology company's stock valued at $431,000 after buying an additional 25 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group increased their price target on Axon Enterprise from $730.00 to $830.00 and gave the company a "buy" rating in a research note on Wednesday, May 14th. Needham & Company LLC increased their price target on Axon Enterprise from $600.00 to $750.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Craig Hallum downgraded Axon Enterprise from a "buy" rating to a "cautious" rating in a research note on Monday, March 10th. Barclays increased their price target on Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Finally, Bank of America increased their price target on Axon Enterprise from $750.00 to $895.00 and gave the company a "buy" rating in a research note on Wednesday, June 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $699.55.

Axon Enterprise Stock Performance

Shares of Axon Enterprise stock opened at $777.32 on Monday. The company has a market capitalization of $60.51 billion, a PE ratio of 187.76, a PEG ratio of 89.48 and a beta of 1.29. Axon Enterprise, Inc has a 12 month low of $279.02 and a 12 month high of $806.64. The company has a current ratio of 2.83, a quick ratio of 2.62 and a debt-to-equity ratio of 0.68. The stock's fifty day simple moving average is $692.15 and its 200 day simple moving average is $625.26.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last released its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The firm had revenue of $603.63 million during the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a return on equity of 5.81% and a net margin of 14.86%. The company's revenue was up 31.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.15 EPS. On average, research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insiders Place Their Bets

In other news, CAO Jennifer H. Mak sold 75 shares of the firm's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $771.81, for a total value of $57,885.75. Following the completion of the transaction, the chief accounting officer now owns 15,240 shares in the company, valued at $11,762,384.40. This trade represents a 0.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Joshua Isner sold 905 shares of the firm's stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $776.39, for a total value of $702,632.95. Following the completion of the transaction, the president now owns 268,735 shares of the company's stock, valued at $208,643,166.65. The trade was a 0.34% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 44,642 shares of company stock worth $30,500,428. Corporate insiders own 5.70% of the company's stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc (NASDAQ:AXON - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.